Skip to main content

Pain management

Discover the products and technologies to help treat your chronic pain patients and access the latest education, training, and support.

Relievant Medsystems is now part of Boston Scientific

Why choose Boston Scientific as your pain management partner

Cognita™ Practice Optimization

Address common challenges in pain management with data-driven support solutions that includes customized insights to help you increase practice efficiency and set your patients up for success.

Cognita Practice Optimization in a circle with sections reading identify, manage and maintain.

MRI Conditionality

Boston Scientific devices with ImageReady™ MRI Conditionality allows patients to safely undergo MRI scans.

Personalized support and therapies for you and your patients

Customized tools and insights to increase your practice efficiency

Dedicated teams to assist with patient education, reimbursement, local marketing, and more

Advanced therapy options for patients at every point of the pain management spectrum

Pain management backed by extensive clinical evidence

Multiple Level 1 RCTs and Real-World studies support the design, efficacy, and efficiency of Boston Scientific's Pain Management therapies.1-6

Pain management training

Find training for spinal cord stimulator systems, radiofrequency ablation, indirect decompression systems, procedures and more.

Tools and resources


Get reimbursement tools for physicians and administrators.

Education for your patients offers personalized content and connection to real people who can answer questions about pain management therapies.

† Superion™ Indirect Decompression System

The WaveWriter Alpha™ SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha and WaveWriter Alpha Prime Spinal Cord Stimulator System. 

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

Indications for use

The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, Diabetic Peripheral Neuropathy of the lower extremities, intractable low back pain and leg pain. Associated conditions and etiologies may be: radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries. Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical candidates, or are pregnant. Warning: Stimulation modes. Only paresthesia-based stimulation mode has been evaluated for effectiveness in the diabetic peripheral neuropathy (DPN) population. Refer to the Instructions for Use provided with the SCS System or for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Indications for use

The Boston Scientific Radiofrequency Generators, associated Radiofrequency Lesion Probes and RF Cannula are indicated for use in procedures to create radiofrequency lesions for the treatment of pain or for lesioning only peripheral nerve tissue for functional neurosurgical procedures. The Boston Scientific RF Injection Electrodes are used for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning of peripheral nerve tissue only. The Boston Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat lesioning of nervous tissue including the Central Nervous System. Warnings: The Boston Scientific RF devices may cause interference with active devices such as neurostimulators, cardiac pacemakers, and defibrillators. Interference may affect the action of these active devices or may damage them. For appropriate guidance, consult the instructions for use for these active devices. Refer to the Instructions for Use provided with Boston Scientific generators, electrodes and cannulas for potential adverse effects, warnings and precautions prior to using these products. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Indications for use

The Superion™ Indirect Decompression System (IDS) is indicated to treat skeletally mature patients suffering from pain, numbness, and/or cramping in the legs (neurogenic intermittent claudication) secondary to a diagnosis of moderate degenerative lumbar spinal stenosis, with or without Grade 1 spondylolisthesis, having radiographic evidence of thickened ligamentum flavum, narrowed lateral recess, and/or central canal or foraminal narrowing. The Superion™ Interspinous Spacer is indicated for those patients with impaired physical function who experience relief in flexion from symptoms of leg/buttock/groin pain, with or without back pain, who have undergone at least 6 months of non-operative treatment. The Superion Interspinous Spacer may be implanted at one or two adjacent lumbar levels in patients in whom treatment is indicated at no more than two levels, from L1 to L5. Contraindications, warnings, precautions, side effects. The Superion Indirect Decompression System (IDS) is contraindicated for patients who: have spinal anatomy that prevent implantation of the device or cause the device to be unstable in situ (i.e., degenerative spondylolisthesis greater than grade 1), Cauda equina syndrome, or prior decompression or fusion at the index level. Refer to the Instructions for Use provided on for additional Indications for Use, contraindications information and potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.


1. Wallace MS, North JM, Phillips GM, et al. Combination therapy with simultaneous delivery of spinal cord stimulation modalities: COMBO randomized controlled trial. Pain Manag. 2023;13(3):171-184. (N=89)
2. Thomson SJ, Tavakkolizadeh M, Love-Jones S, et al. Effects of rate on analgesia in kilohertz frequency spinal cord stimulation: results of the proco randomized controlled trial. Neuromodulation. 2018;21(1):67-76.
3. North J, Loudermilk E, Lee A, et al. Outcomes of a multicenter, prospective, crossover, randomized controlled trial evaluating subperception spinal cord stimulation at ≤1. 2 khz in previously implanted subjects. Neuromodulation. 2020;23(1):102-108.
4. Metzger CS, Hammond MB, Pyles ST, et al. Pain relief outcomes using an SCS device capable of delivering combination therapy with advanced waveforms and field shapes. Expert Rev Med Devices. 2020;17(9):951-957.
5. Paz-Solís J, Thomson S, Jain R, Chen L, Huertas I, Doan Q. Exploration of high- and low-frequency options for subperception spinal cord stimulation using neural dosing parameter relationships: the halo study. Neuromodulation. 2022;25(1):94-102.
6. Veizi E, Hayek SM, North J, et al. Spinal cord stimulation (Scs) with anatomically guided (3d) neural targeting shows superior chronic axial low back pain relief compared to traditional scs-lumina study. Pain Med. 2017;18(8):1534-1548.
7. Provenzano D, et al. Significant Pain Relief and Treatment Satisfaction Following Radiofrequency Ablation Prospective, Multicenter Study (RAPID) [Abstract]. Fifth Annual Meeting of the American Society of Pain and Neuroscience Society, July 13-16, 2023 (N=289 as of July 2023, ongoing study)
8. Nunley PD, Patel VV, Orndorff DG, Lavelle WF, Block JE, Geisler FH. Five-year durability of stand-alone interspinous process decompression for lumbar spinal stenosis. Clin Interv Aging. 2017;12:1409-1417. (N=88)